Samsung Bioepis begins to nullify Herceptin’s patent
Samsung Bioepis has started to prepare for a launch of Herceptin(generic name: trastuzumab) biosimilar, a breast cancer treatment, in Korea.
According to the Intellectual Property Tribunal, Samsung Bioepis filed a (defensive) confirmation trial for the scope of the patent ‘Protein Purification ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
